History of Benzodiazepines
Benzodiazepines, commonly known as “benzos,” have played a pivotal role in treating anxiety, insomnia, and related conditions since the 1960s. Discovered by Leo Sternbach in 1955, chlordiazepoxide (Librium) became the first benzodiazepine on the market in 1960. Diazepam (Valium), launched in 1963, quickly gained widespread use and became one of the most prescribed medications of its time. By the 1970s, Valium was the top-selling drug in the United States, reflecting society’s growing reliance on pharmacological solutions for mental health conditions.
Trends in Prescribing
Over the decades, the way clinicians prescribe benzodiazepines has shifted significantly. Initially, they were viewed as safer alternatives to barbiturates and were frequently prescribed. However, as awareness of their addictive potential grew in the 1980s and 1990s, prescribing practices became more cautious. Despite this shift, benzodiazepines remained a mainstay for treating chronic anxiety and insomnia.
In 2017, the U.S. Food and Drug Administration (FDA) issued a black box warning, underscoring the risks of addiction, dependence, and withdrawal, especially when benzodiazepines are used with opioids. This warning marked a significant change in how clinicians approach prescribing these medications.
Chronic Use and Risk of Addiction
Chronic benzodiazepine use—defined as daily use for more than three months—dramatically increases the risk of addiction. Randomized controlled trials (RCTs) and meta-analyses consistently show that long-term use leads to physical dependence and addiction. One meta-analysis reported that 44% of chronic users develop dependence.1 The addictive potential arises from alterations in the brain’s GABAergic system, leading to tolerance and withdrawal symptoms when the medication is discontinued.
Benzodiazepine addiction manifests through symptoms such as cravings, difficulty reducing use despite adverse effects, and withdrawal symptoms like anxiety, insomnia, and seizures. Even therapeutic doses can result in addiction, particularly in individuals with a history of substance use or psychiatric disorders.2
Safety in the Elderly
Benzodiazepine use in older adults presents additional safety concerns. Older patients face a higher risk of adverse effects, including cognitive impairment, falls, and fractures. Studies also link benzodiazepine use to an increased risk of dementia and mortality in this population.3 The American Geriatrics Society advises against using benzodiazepines in elderly patients due to these heightened risks.
Deprescribing Strategies
Deprescribing benzodiazepines, especially in long-term users, requires a careful and patient-centered approach. The Ashton Manual, developed by Professor Heather Ashton, provides a detailed guide for tapering off benzodiazepines safely. It advocates for gradual dose reduction and psychological support to manage withdrawal symptoms.4
Current guidelines recommend a slow taper, reducing the dose by 10-25% every 2-4 weeks, depending on the patient’s response. Cognitive-behavioral therapy (CBT) can also help address underlying conditions such as anxiety or insomnia during the tapering process.5 No single method works for all patients.
Conclusion
The risks associated with chronic benzodiazepine use, particularly addiction and physical dependence, are well-established. Although benzodiazepines provide effective short-term relief for anxiety and insomnia, their long-term use poses substantial risks, especially for elderly patients. Deprescribing requires a structured plan and ongoing support to minimize withdrawal and mitigate dependence.
Striking a balance between the therapeutic benefits and the risks of addiction is important to prevent overuse while ensuring that patients who need these medications can use them safely. Educating patients and providers on the risks and safe use of benzodiazepines will help maintain this balance and ensure appropriate prescribing practices.
References
1. Voshaar RC, Couvee JE, Van Balkom AJ, Mulder PG, Zitman FG. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry. 2006;189:213-220.
2. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72(2):136-142.
3. Billioti de Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of dementia: prospective population-based study. BMJ. 2012;345.
4. Ashton H. The Ashton Manual: Benzodiazepines: How They Work and How to Withdraw. Available from: https://www.benzo.org.uk/manual/
5. Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339-351.
